These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 28791656)
1. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. Westphal M; Maire CL; Lamszus K CNS Drugs; 2017 Sep; 31(9):723-735. PubMed ID: 28791656 [TBL] [Abstract][Full Text] [Related]
2. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476 [TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor as a therapeutic target in glioblastoma. Kalman B; Szep E; Garzuly F; Post DE Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987 [TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Hegi ME; Rajakannu P; Weller M Curr Opin Neurol; 2012 Dec; 25(6):774-9. PubMed ID: 23007009 [TBL] [Abstract][Full Text] [Related]
5. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Taylor TE; Furnari FB; Cavenee WK Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382 [TBL] [Abstract][Full Text] [Related]
7. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Yewale C; Baradia D; Vhora I; Patil S; Misra A Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842 [TBL] [Abstract][Full Text] [Related]
9. A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma. Kwatra MM Curr Cancer Drug Targets; 2017; 17(3):290-296. PubMed ID: 28029074 [TBL] [Abstract][Full Text] [Related]
10. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981 [TBL] [Abstract][Full Text] [Related]
11. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
12. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation. Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489 [TBL] [Abstract][Full Text] [Related]
14. Current and emerging EGFR therapies for glioblastoma. Artene SA; Tuţă C; Dragoi A; Alexandru O; Stefana Oana P; Tache DE; Dănciulescu MM; Boldeanu MV; Siloşi CA; Dricu A J Immunoassay Immunochem; 2018; 39(1):1-11. PubMed ID: 29308973 [TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities. Ezzati S; Salib S; Balasubramaniam M; Aboud O Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993 [TBL] [Abstract][Full Text] [Related]
16. Enhanced cancer therapy with the combination of EGFR and VEGFR-2 targeting in an orthotopic glioblastoma model. Diao Y; Tian XH; Huang YL; Chen LK; Lin XN; Zhuang ZW J Chemother; 2010 Dec; 22(6):407-12. PubMed ID: 21303749 [TBL] [Abstract][Full Text] [Related]
17. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558 [TBL] [Abstract][Full Text] [Related]
19. mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy. Zheng Y; Su C; Zhao L; Shi Y J Nanobiotechnology; 2017 Oct; 15(1):66. PubMed ID: 28978341 [TBL] [Abstract][Full Text] [Related]
20. Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment. Shaghaghi Z; Hosseinimehr SJ Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):323-339. PubMed ID: 28875828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]